|Overview: Radioligands enable academic and industry researchers to directly study the biochemical and functional binding responses of a wide range of cellular receptor sites at the molecular level, without the variables associated with non-radiometric methods. Today, with more than 300 NEN® radioligands available, scientists are able to identify, characterize and manipulate ligand-receptor interactions, while still employing radiometric detection as the gold standard of measurement for the discovery and development of drugs in today’s pharmaceutical market.
This webinar will examine the following:
- Unique properties and characteristics of radioligands
- Radioligand Binding Assay applications and feasibility
- Methods for use of reference radioligands in primary screening, profiling, affinity and kinetics
Points to learn from the webinar:
- The ability to accelerate the pace and clinical relevance of drug discovery research
- The use of radioligands to achieve hit identification, lead optimization, and liability studies
- Radiometric Detection as a simple and flexible assay using biologically equivalent radioligands
- Selection of platforms (membranes/microplates/SPA beads) and instrumentation
Rajendrani (Raj) Mukhopadhyay, Ph.D.
Freelance Science Writer and Editor
Host for this Webinar:
Jeffrey Killian, Ph.D. Director, Bio-discovery Global Technical Support
Scott Perschke, M.S. Director, Assay Development Caliper Discovery Alliances and Services (formerly NovaScreen Biosciences)
Martha Widra Manager/Contract Manager, Environmental Health & Safety Coordinator Coordinator, Immunology Caliper Discovery Alliances and Services (formerly NovaScreen Biosciences)